Related Experiment Video
Updated: Sep 13, 2025
07:34
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
2.7K
Gut Hormones and Inflammatory Bowel Disease
1Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA.
Biomolecules
|July 29, 2025
Summary
Gut hormones like GLP-1 and GIP regulate metabolism and immunity, offering potential IBD treatments. Combination therapies show promise but require more clinical research for safety and efficacy in obese patients.
Area of Science:
- Gastroenterology
- Metabolic Research
- Immunology
Background:
- Obesity-induced inflammation compromises gut barrier integrity, contributing to inflammatory bowel disease (IBD).
- Gut hormones, including glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucose-dependent insulinotropic polypeptide (GIP), peptide YY (PYY), cholecystokinin (CCK), and apolipoprotein A4 (APOA4), are critical regulators of host metabolism and mucosal immunity.
- These hormones present potential therapeutic avenues for IBD management.
Purpose of the Study:
- To review the known mechanisms by which gut hormones influence gut barrier function and immunity.
- To explore the therapeutic potential of targeting gut hormones for IBD treatment, particularly in the context of obesity and metabolic dysfunction.
- To discuss synergistic interactions between gut hormones and their implications for combination therapies.
Main Methods:
- Literature review of preclinical and clinical studies on gut hormones and their role in IBD.
- Analysis of mechanisms involving GLP-1, GLP-2, GIP, PYY, CCK, and APOA4 in gut health and inflammation.
- Evaluation of evidence for combination hormone therapies and their clinical application.
Main Results:
- GLP-1, GLP-2, GIP, PYY, CCK, and APOA4 demonstrate beneficial effects on gut barrier integrity, epithelial repair, immune modulation, and inflammation reduction in preclinical models.
- Synergistic effects observed with co-administration or indirect interactions (e.g., PYY-stimulated APOA4) suggest enhanced therapeutic benefits.
- Dual GIP/GLP-1 receptor agonists show metabolic and inflammatory improvements but are linked to gastrointestinal side effects in clinical use.
Conclusions:
- Gut hormones hold significant therapeutic promise for IBD, especially in patients with obesity or metabolic issues.
- Combination hormone therapies may offer superior efficacy, but further research is needed to optimize strategies and ensure safety.
- Future clinical trials should focus on evaluating combination therapies, understanding shared pathways, and tailoring treatments for IBD patients.
Keywords:
apolipoprotein A4cholecystokininglucagon-like peptide-1glucagon-like peptide-2glucose-dependent insulinotropic polypeptideinflammatory bowel diseaseobesitypeptide YYMore Related Videos
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
390
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
390
01:30Inflammatory Bowel Disease II: Crohn's Disease
387
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
387
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
422
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
422
01:29Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
01:17Chronic Bowel Disorders: Introduction
541
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
326
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
326